logo
Menu

This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Canakinumab (ILARIS®) for Cardiovascular risk reduction – Add on therapy

< Back

Canakinumab (ILARIS®) for Cardiovascular risk reduction – Add on therapy

Drugs

Cardiovascular Disease and Vascular Surgery

September 2017


Cardiovascular disease (CVD) is a general term that refers to all conditions affecting the heart and blood vessels (circulation). These include angina, heart attack (also known as myocardial infarction), heart failure, stroke, and a number of diseases that affect the blood vessels.
CVD is usually associated with a build-up of fatty deposits inside the blood vessels (arteries) which make the vessels become narrowed (atherosclerosis). The body also reacts to the fatty deposits by sending white blood cells to the blood vessels; this process is called inflammation. The fatty deposits along with the inflammation lead to reduction of the blood supply to the heart and significantly increase the risks of heart attack and other types of cardiovascular diseases.
Canakinumab is a medicine being developed to target inflammation. It is the first and only agent which has shown that by selectively targeting some specific biomarkers of inflammation, it significantly reduces cardiovascular risks. Canakinumab is currently being developed to be used as an add-on therapy for patients who have had a prior heart attack and have a higher risk of further cardiovascular disease.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment



 

Connect to the Innovation Observatory

Twitter

Load More Related Posts

Get Alerts